BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC.
About BiTE Antibodies
BiTE(R) antibodies are designed to direct the body’s cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.
CONTACT: Jennifer Neiman, Director, Corporate Communications, Micromet,
Inc., +1-240-235-0246, Jennifer.neiman@micromet-inc.com; or Susan Noonan,
Managing Partner, S.A. Noonan Communications, +1-212-966-3650,
susan@sanoonan.com
Web site: http://www.micromet-inc.com/
